1. NBTX remains a late-stage clinical biotech focused on innovative treatments. 2. The company holds over 25 patent families in key therapeutic areas. 3. As of November 30, 2025, NBTX has over 50 million voting rights. 4. NBTX has been listed on Nasdaq since December 2020. 5. Innovative physics-based approaches could enhance treatment outcomes significantly.
FAQ
Why Bullish?
Nanobiotix’s focus on disruptive biotechnology indicates potential for strong future growth, similar to other biotech firms like Moderna, which skyrocketed post-FDA approvals.
How important is it?
The article provides critical insights into NBTX’s corporate structure and future prospects that could drive investor interest.
Why Long Term?
The company's ongoing research and patent portfolio suggest sustained potential—historically, biotechs often see valuation increases as clinical developments materialize.
NBTX Announces Voting Rights and Shares Capital Update
PARIS, Dec. 17, 2025 – Nanobiotix (Nasdaq: NBTX), a pioneering clinical biotechnology company, has released its latest update regarding outstanding shares and voting rights in compliance with regulatory requirements. This announcement is critical for shareholders and investors as it outlines essential specifics about the company's voting rights structure.
Key Financial Data as of November 30, 2025
As per the regulations stipulated in articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers), the updated figures are as follows:
- Number of Shares Outstanding: 48,401,118
- Total Number of Voting Rights: 50,101,699
- Total Voting Rights Theoretical: 50,079,581
About Nanobiotix (NBTX)
Founded in 2003 and headquartered in Paris, Nanobiotix is at the forefront of biotechnology, developing innovative, physics-based therapeutic solutions aimed at enhancing treatment outcomes for patients. Listed on both Euronext Paris since 2012 and the Nasdaq Global Select Market since December 2020, Nanobiotix is dedicated to advancing healthcare through its sophisticated nanotechnology platforms, with over 25 patents covering applications in:
- Oncology
- Bioavailability and biodistribution
- Disorders of the central nervous system
With subsidiaries in Cambridge, Massachusetts, as well as other locations, Nanobiotix is committed to pushing the boundaries of what is known to improve human health.
Understanding Voting Rights Calculations
The total number of theoretical (or “gross”) voting rights is crucial for determining shareholder thresholds. According to Article 223-11 of the AMF General Regulations, this total includes all shares attached to voting rights, including those whose rights are currently suspended. On the other hand, the total number of exercisable (or “net”) voting rights reflects shares without voting rights suspensions, specifically those held in treasury by the company. This information is essential for maintaining transparency with the public and shareholders.
Contact Information
For more details, shareholders and interested parties can reach out to:
- Brandon Owens, VP, Communications: +1 (617) 852-4835, contact@nanobiotix.com
- Joanne Choi, VP, Investor Relations (US): +1 (713) 609-3150
- Ricky Bhajun, Director, Investor Relations (EU): investors@nanobiotix.com
- Caroline Hardy, Media Relations (France): +33 06 70 33 49 50, carolinehardy@outlook.fr
- Becky Lauer, Media Relations (Global): +1 (646) 286-0057, uncappednanobiotix@uncappedcommunications.com